Drugs / Prolyl Endopeptidase
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT04788797 Comparator | Mar 2021 → Jul 2022 | celiac disease | Dr. C. Bonorino Udaondo Gastroenterology Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Prolyl Endopeptidase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04788797 ↗ |
| Known as | GliadinX | “AN-PEP (GliadinX®)” NCT04788797 ↗ |
| Modality | Protein / enzyme biologic | “AN-PEP, an Aspergillus niger derived endopeptidase” NCT04788797 ↗ |